Instituto Nacional de Salud, Ministerio de Salud, San Salvador, El Salvador.
Departamento de Laboratorio Nacional de Salud Pública, Ministerio de Salud, San Salvador, El Salvador.
J Antimicrob Chemother. 2021 Apr 13;76(5):1155-1159. doi: 10.1093/jac/dkab010.
Invasive meningococcal disease (IMD) is an acute, highly transmissible and potentially fatal disease caused by Neisseria meningitidis. Prompt antimicrobial therapy and prophylaxis are recommended, where penicillin or ciprofloxacin are the available choices. However, the emergence of resistant isolates of N. meningitidis poses a challenge for antimicrobial therapy.
To describe the clinical, epidemiological and biological characteristics of six penicillin- and ciprofloxacin-resistant, culture-confirmed IMD cases reported in El Salvador, Central America, between 2017 and 2019.
Following the detection of six patients presenting with IMD in El Salvador, clinical data were collected and epidemiological action plans conducted. Isolates were subjected to antimicrobial susceptibility testing by broth microdilution and WGS for genotyping and molecular characterization analysis, including phylogeny comparison with global sequences available from public databases.
A total of six IMD cases caused by N. meningitidis serogroup Y, resistant to both penicillin (MIC >8.0 mg/L) and ciprofloxacin (MIC 0.125 mg/L), were detected from 2017 to 2019. Genomic analysis showed that penicillin resistance was mediated by the production of β-lactamase ROB-1. Ciprofloxacin resistance was attributed to an amino acid substitution in DNA gyrase (T91I). All isolates were classified as ST3587, clonal complex 23, and were genetically highly similar, based on core-genome SNP analysis.
To the best of our knowledge, we report the first cases of MDR N. meningitidis causing IMD in Latin America. Our findings highlight the emergence of this potential public health threat, with a profound impact on the efficacy of IMD treatment and prophylaxis protocols.
侵袭性脑膜炎奈瑟菌病( IMD )是一种由脑膜炎奈瑟菌引起的急性、高度传染性且可能致命的疾病。建议及时使用抗生素治疗和预防,可供选择的抗生素包括青霉素或环丙沙星。然而,脑膜炎奈瑟菌耐药株的出现对抗生素治疗提出了挑战。
描述 2017 年至 2019 年期间在中美洲萨尔瓦多报告的 6 例经培养证实的耐青霉素和环丙沙星的侵袭性脑膜炎奈瑟菌病病例的临床、流行病学和生物学特征。
在萨尔瓦多发现 6 例 IMD 患者后,收集了临床数据并制定了流行病学行动计划。对分离株进行药敏试验,采用肉汤微量稀释法和 WGS 进行基因分型和分子特征分析,包括与公共数据库中全球序列进行系统发育比较。
2017 年至 2019 年期间共检测到 6 例由脑膜炎奈瑟菌血清群 Y 引起的 IMD 病例,这些菌株对青霉素(MIC>8.0mg/L)和环丙沙星(MIC 0.125mg/L)均耐药。基因组分析表明,青霉素耐药性是由β-内酰胺酶 ROB-1 的产生介导的。环丙沙星耐药归因于 DNA 回旋酶的氨基酸替换(T91I)。所有分离株均被分类为 ST3587,克隆复合体 23,基于核心基因组 SNP 分析,遗传上高度相似。
据我们所知,我们报告了拉丁美洲首例 MDR 脑膜炎奈瑟菌引起的 IMD 病例。我们的研究结果强调了这种潜在的公共卫生威胁的出现,对 IMD 治疗和预防方案的疗效产生了深远影响。